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Abstract: With the increasing number of patients affected with metabolic diseases such as type 2
diabetes, obesity, atherosclerosis and insulin resistance, academic researchers and pharmaceutical
companies are eager to better understand metabolic syndrome and develop new drugs for its
treatment. Many studies have focused on the nuclear receptor peroxisome proliferator-activated
receptor gamma (PPARγ), which plays a crucial role in adipogenesis and lipid metabolism. These
studies have been able to connect this transcription factor to several human metabolic diseases.
Due to obvious limitations concerning experimentation in humans, animal models—mainly mouse
models—have been generated to investigate the role of PPARγ in different tissues. This review
focuses on the metabolic features of human and mouse PPARγ-related diseases and the utility of the
mouse as a model.
Keywords: PPARγ expression; human mutations; mouse models; metabolic syndrome; lipodystrophy;
ligand activation
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors
of the nuclear receptor superfamily [1]. There are three PPARs in mammals: PPARα, PPARβ/δ
and PPARγ. The PPARs forms obligatory heterodimers with retinoid X receptors (RXRs) and bind
to PPAR-responsive elements (PPRE), which regulate the expression of different genes involved in
adipogenesis, lipid metabolism and inflammation. PPARs have modular structures containing a
N-terminal A/B region with a transactivation domain (AF1), a DNA binding domain (DBD) with
two zinc-finger motifs and a C-terminal ligand-binding domain (LBD) with the ligand-dependent
transactivation function (AF2) [2,3]. PPARγ was first identified in 1992 in Xenopus [4] and then
in 1993 in mice [5]. PPARγ is highly expressed in white adipose tissue (WAT) and brown adipose
tissue (BAT), where it plays a critical role in adipogenesis, lipid metabolism and insulin sensitivity.
PPARγ is expressed at much lower levels in other metabolic tissues, such as liver and muscle
but shows a relatively high expression in placenta, where it is a regulator of vascularization [6].
PPARγ is a modulator of lipid metabolism and inflammatory function in macrophages and dendritic
cells [7–9]. Comparing the expression of PPARγ in human and mouse tissues, both show a very
similar expression pattern, suggesting conserved function of PPARγ across species (Figure 1) [10].
PPARγ has two isoforms: PPARγ1 and PPARγ2. While PPARγ1 is expressed in many tissues, PPARγ2
is adipose tissue-specific under normal physiological conditions, however it is also expressed in
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macrophages [11]. These two isoforms differ at the N-terminal end of the protein, where PPARγ2
contains an additional 28 amino acids in humans and 30 amino acids in mouse that are absent in
PPARγ1. The amino acid sequence of human and mouse PPARγ is highly conserved, with only nine
amino acids are differing in the PPARγ1 (Figure 2). This suggests a very similar way of folding and
DNA binding with RXR [12]. PPARγ can be modulated by posttranslational modifications such as
ubiquitination, acetylation, phosphorylation and sumoylation. These modifications confer cell and
tissue specificity [13,14].
Within the last two decades, PPARγ became a focus of attention as a transcription factor implicated
in metabolic syndrome. Metabolic syndrome is a concerning public health issue worldwide, which is
characterized by a cluster of different symptoms, including obesity, insulin resistance, hyperglycemia,
hypertension, hypertriglyceridemia and decreased serum HDL cholesterol levels [15]. All of the
aforementioned symptoms contribute to cardiovascular disease, the leading cause of death throughout
the world. Researchers go to great lengths attempting to understand the human physiology and
uncover those genetic, physiological and environmental changes, which contribute to impair metabolic
processes. Plenty of studies have demonstrated the central role of PPARγ in metabolic diseases [16].
Thiazolidinediones (TZDs) are synthetic ligands and potent activators of PPARγ; they have been
amply used in treating type 2 diabetes (T2D) in the past. Rosiglitazone and pioglitazone have
been withdrawn from the US and European market due to critical cardiovascular diseases and
bladder cancer as side effects [14,17,18]. Insulin resistance is a major player in the pathogenesis
of metabolic syndrome. Furthermore, PPARγ agonists have been reported to modulate insulin
sensitivity and glucose metabolism. Thus, it is of general research interest the finding of new
PPARγ–modulators that could improve insulin sensitivity with less important side effects. However,
clinical investigations involving human subjects have ethical and methodological limitations, creating
a need for a physiologically relevant model organism. This need was addressed by using mice as a
model organism for metabolic syndrome. Conversely, using model systems to investigate a biological
process always raise the question: how good is the model that we use? In this review, we center our
attention on the new developments of the field to answer this question.
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Figure 1. PPARγ tissue distribution in human and mouse. We re-analyzed the expression data set 
GDS596 (human) and GDS592 (mouse) from Su et al. [10] available on NCBI GEO database 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1133). The expression values were 
normalized to median and the tissues were selected based on the levels of PPARγ expression. 
Metabolic tissues are highlighted in blue. WAT = white adipose tissue, BAT = brown adipose tissue, 
NA = data not available. 
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Figure 1. PPARγ tissue distribution in human and mouse. We re-analyzed the expression data set
GDS596 (human) and GDS592 (mouse) from Su et al. [10] available on NCBI GEO database (http:
//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1133). The expression values were normalized
to median and the tissues were selected based on the levels of PPARγ expression. Metabolic tissues are
highlighted in blue. WAT = white adipose tissue, BAT = brown adipose tissue, NA = data not available.
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Figure 2. Comparison of PPARγ protein homology between human and mouse. We used Ensembl 
database to obtain the protein sequences and then we compared the human and mouse PPARγ 
sequences with Clustal 2.1 multiple sequence alignment program. For protein modeling of PPARγ 
Phyre2 web portal was used and for visualization Geneious 9.1.4 software was applied. 
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ere are several mutations described in the PPARγ gene that affects metabolism traits in humans.
These mutations have been classified previously as followed: common poly orphisms (Pro12Ala,
His477His), dominant-negative (Val290M t, Cys162Tyr), haploinsufficient mutations (Arg425Cys,
Phe388Leu), gain of function mutations (Pro115Gln) and promoter variants (P2 C-689T, P4 A-14G) [19].
In 1997, the most studied and well-characterized polymorphism in epidemiologic studies, Pro12Ala
(rs1801282), was first described (Table 1). Susceptibility to T2D with the Pro12 allele and resistance with
Ala12 allele was described later [20,21]. It has be n hypothesized that the increas insulin clear nce
a d sensitivity in Ala12 allele are due to improv d lipolysis [22]. Furthermore, the association of
LPL activity in vitro and in vivo has been reported [20,23]. In a large meta- nalysis, the Pro12Ala
SNP has been found to increase b dy mass index (BMI) [24]. The association of cardiovascular
disease (CVD) and th Pro12Ala polymorphism has been widely studied. However, the results are
contradictory. Ridker et al. found a protective role of the Ala allele for myocardi l infarction risk [25].
However, in 2004 Tobin and colleagues did not find th same protectiv effect [26]. A more recent
meta-analysis found an increased risk of CVD of the Ala allele in Caucasians patients but not in an
Asia population [27]. Importa tly, in gen me-wide association studies (GWAS), the Pro12Ala variant
was among those found in type 2 monoge ic diabetes [28]. Moreov r, this allel also inter cts with
BMI in regard to increasing insulin resista ce [29]. Int re tingly, PPARγ rs1801282 polymorphism has
also been studied in several populations, and it exhibits population-based susceptibility to different
metabolic traits. In overweight Br zilian pubertal sample, this polymorphism showed higher risks of
altered insulin levels [30]. M anwhile, Pro12Ala could pr dict BMI, overweight, and total cholesterol
in females but not in male Taiwanese patients [31]. In children diagnosed with T2D the Pro12Ala
polymorphism of PPARγ was significantly associated with obesity and T2D [32]. H wever, in a
Japanese cohort, this polymorphism w s not associated with BMI, and vi ceral and subcutaneous
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fat accumulation assessed by computed tomography [33]. Furthermore, Pro12Ala allele is a strong
predictor for T2D susceptibility in Asian Indian Sikhs and Chinese population [34,35]. In Russian
populations, this variant is associated with insulin sensitivity in type 2 diabetic and normoglycemic
subjects [36]. PPARγ Pro12Ala polymorphism is associated with insulin sensitivity and BMI in patients
with polycystic ovary syndrome (PCOS) [37]. Importantly, lifestyle interventions appeared to be
allele-dependent. The association of Pro12 PPARγ carriers with T2D and low physical activity has
been described [38]. PPARγ Pro12Ala variant improves glucose homeostasis as a result of regular
exercising with a GWAS approach according to results from the HERITAGE Family Study [39].
Interaction of PPARγ Pro12Ala with dietary fat influences plasma lipids in subjects who are at risk
for cardiometabolic diseases [40]. Furthermore, the PPARγ SNP rs1175544 influences the weight loss
in a longitudinal study with short-term calorie restriction [37]. Importantly, Pro12Ala variant did
not affect the response of pioglitazone treatment in patients with T2D (Figure 3) [41]. However, in a
genome-wide study using ChIP-seq, RNA-seq and Gro-seq, Soccio et al. showed that PPARγ binding
and the response to rosiglitazone depends on SNPs in human and mouse subcutaneous fat tissues and
cell lines respectively [42].
Table 1. Summary of human PPARγ polymorphism associated to metabolic syndrome conditions.
Polymorphism Metabolic Traits Involved References
Pro12Ala
T2D [20,32]
Monogenic diabetes [21]
Higher BMI [24,32]
Altered insulin levels [30]
Insulin sensitivity [36]
BMI and insulin sensitivity in PCOS [37]
P467L V290M Insulin resistance, liver steatosis, T2D and hypertension [43]
Promoter variants polymorphism
rs29722164 rs11128598 rs17793951
rs1151996 rs1175541 rs3856806
Deterioration of B-cell function [44]
V162 Increase total cholesterol and LDL-cholesterol levels [45]
C161T CHD in patients with T2D [46]
C1431T Altered fasting serum lipids and risk factor for CHD [47]
S289C Dyslipidemia, obesity and hypertension [48]
H449L Hypertriglyceridemia, insulin resistance and hepaticsteatosis, FPLD3 [49]
R165T L339X FPLD3 and severe hypertension [50]
c.1040A > C FPLD3, Diabetes Mellitus, hypertension and dyslipidemia [51]
Biallelic mutation E138V and R164W CGL, hypertriglyceridemia, diabetes mellitus, pancreatitisand renal failure [52]
T2D = type 2 diabetes mellitus; BMI = body mass index; PCOS = polycystic ovarian syndrome; LDL = low-
density lipoprotein; CHD = coronary heart disease; FPLD3 = familiar partial lipodystrophy 3; CGL = congenital
general lipodystrophy.
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The association between five PPARγ promoter variants and T2D has been described in T2D
postmenopausal women [53]. In addition, different PPARγ polymorphisms (rs2972164, rs11128598,
rs17793951, rs1151996, rs1175541, and rs3856806), contributed to the deterioration of β-cell function in
Mexican Americans population with T2D risk [44]. In a large cohort of T2D cases and controls from
multiple studies and ethnic groups, Majithia et al. in 2014 described unidentified PPARγ variants.
Nine of these 49 variants have reduced activity in adipocyte differentiation and were associated with a
higher risk of T2D [54] (Table 1).
Hypercholesterolemia and hypertriglyceridemia have also been associated with PPARγ
polymorphisms in a large meta-analysis in 2012 by Asselbergs et al. [55]. Moreover, PPARα V162
allele increases total cholesterol and LDL-cholesterol levels. This effect was reduced by carrying
the PPARγ T161 allele in patients with non-diabetic coronary heart disease (CHD) [45]. Another
polymorphism associated with CHD is C161T in patients with T2D. The phenotype of this SNP was
weakening with the presence of P12P homozygote genotype [46]. Moreover, in an Italian cohort, the
93695C > T PPARγ promoter polymorphism was found to have a protective role in acute coronary
syndrome [56]. Furthermore, the C1431T PPARγ polymorphism was associated not only with altered
plasma lipids during fasting but also with higher risk of an angiography defined CVD [47]. However,
in a large meta-analysis there was no statistically significant difference of serum lipids levels in an
Asian population carrying this SNP [57].
Epigenetic changes of the PPARγ gene locus have also been found in metabolic syndrome-related
diseases. Recently Kokosar et al. investigate methylation and gene expression in adipose tissue in women
with PCOS. Methylation and gene expression of PPARγ was inversely correlated in this study [58].
Furthermore, Nilsson et al. described differential DNA methylation in 15,627 sites, representing
7046 genes including PPARγ in adipose tissue from patients with T2D compared to control subjects [59].
PPARγ loss of function mutations have been reported in colorectal cancers. Not surprisingly
in 2010 a novel germline mutation in this gene (S289C) was found in a patient with dyslipidemia,
obesity, and hypertension not associated with T2D and a large intestine polyp that progressed to
adenocarcinoma [48].
2.2. PPARg Mutations Associated with Lipodystrophy
Lipodystrophy is a syndrome characterized by adipose tissue deficiency; this results in ectopic
lipid accumulation in organs and causes non-alcoholic fatty liver disease (NAFLD), reduced blood
leptin insulin resistance and T2D [60,61]. Human lipodystrophies are genetic or acquired and may
be partial or generalized. Familial partial lipodystrophies (FPLD) are diseases relating to abnormal
adipose tissue topography and reduction in total fat mass. The FPLDs have been subclassified into three
groups: FPLD1, FPLD2 or FPLD3. A set of mutations in PPARγ gene is associated with FPLD3 (Table 1).
Patients with dominant-negative mutations in a single allele of PPARγ have partial lipodystrophy
and insulin resistance. The FPLD3 clinical presentation is characterized by a deficiency of limb and
gluteal fat, meanwhile abdominal and facial fat is usually preserved [62]. The presentation is usually
in adulthood, but insulin resistance and lipodystrophy have been described in prepubertal children
as well [63–65]. In the patients carrying PPARγ F388L mutant, the transcriptional levels of PPARγ
were threefold lower than in the wild type in luciferase assay [64]. Two heterozygous mutations
(P467L and V290M) were reported in the PPARγ ligand-binding domain and the clinical presentation
in three patients was severe insulin resistance, liver steatosis, T2D and hypertension at an early age
(Figure 3). Later, patients carrying these mutations were found to have partial lipodystrophy as
assessed by a complete evaluation of body composition and fat distribution.
There have been approximately 60 patients in the world identified with FPLD3. The most
recent reported mutations in the PPARγ gene that has been found in patients with FPLD3 are
summarized below.
The PPARγ mutation D424N is located in the ligand-binding domain, and the patients carrying
this mutation exhibited a loss of function; which is partially restored by adding the PPARγ agonist
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rosiglitazone during in vitro analysis using luciferase assays [66]. PPARγ H449L mutation was
associated with hypertriglyceridemia, insulin resistance, and NAFLD in four patients related with
variable severity in the clinical features. Three subjects presented diabetes or impaired glucose
tolerance. Pioglitazone therapy in these three patients resulted in a modest improvement in their
metabolic control and consistent menstrual cycles in the two female subjects [49]. Novel mutations
in PPARγ (R165T and L339X) linked to FPLD3 are associated with a defective transrepression
of cellular RAS leading to cellular dysfunction, contributing to the specific FPLD3-linked severe
hypertension [50]. Recently, a heterozygous PPARγ mutation c.1040A > C was identified in all five
patients of a family. The resulting amino acid substitution is predicted to disrupt critical molecular
interactions at the ligand-binding domain [51]. All pathogenic mutations described until 2014 were
heterozygous and located in the DNA- or ligand-binding domains of the PPARγ protein. Most of
them show dominant negative activity [43,67]. Recently, Dyment et al. described a biallelic mutation
at PPARγ that causes a congenital generalized lipodystrophy (E138V and R164W). A female patient
presented a particular phenotype since birth: clear general absence of adipose tissue, later during
childhood developed hypertriglyceridemia, pancreatitis, refractory diabetes, irregular menses and
renal failure [52]. These new mutations open the possibility of analyzing PPARγ sequence in patients
with congenital generalized lipodystrophy (CGL) when no mutation in well-established CGL causing
genes could be found.
Further studies investigating PPARγ binding and general gene expression are needed in patients
with partial lipodystrophies and human common polymorphisms. Also iPS technology should be
used to the generation of patient-specific cell lines and the differentiation of such cells to adipocytes
and other cell types should allow disease-in-a-dish type experiments and molecular dissection of the
mutant receptor to cellular processes.
3. Mouse Models for Study the Role of PPARγ in Metabolic Diseases
3.1. PPARγ Full Body Knockout Mice
The first attempts to generate whole body PPARγ knockout (KO) mice showed that loss of PPARγ
caused impaired terminal differentiation of the trophoblast and placental vascularization resulting
in utero lethality of null embryos tetraploid-rescued PPARγ-null mice survived and showed lack
of adipose tissues, which established the essential role of PPARγ in adipogenesis (Figure 4) [68].
The solution for generating full body PPARγ null mice was the Mox2-Cre-floxed PPARγ (MORE-PG)
KO, in which Cre recombinase is expressed only in epiblast-derived tissues and preserves PPARγ
expression in the trophoblast but only 10% reach adulthood [69]. The characteristics of these mice are:
lipodystrophy, organomegaly, decreased leptin and adiponectin in plasma, insulin resistance, elevated
free fatty acids (FFAs) and hypotension (Table 2). Moreover, these mice show sex-dependent response
to rosiglitazone, which induced regrowth of specific fat depots and improved insulin sensitivity in
female, but not in male mice. In contrast, rosiglitazone improved glucose homeostasis with further
increase in insulin production but not insulin sensitivity in male mice. Due to the high rate of mortality
of this full PPARγ deletion, a tamoxifen inducible whole body PPARγ KO system has been used, and
together with the MORE-PG mice, they showed a different gene expression of clock genes in relevant
metabolic tissues than controls [70].
Expounding on these systems, Sox2Cre is another type of recombination technology for generating
epiblast-specific conditional KO mice [71]. Sox2Cre-floxed PPARγ KO mice escape from embryonic
lethality due to normal placental angiogenesis. Several diseases affect these full-body PPARγ deficient
mice, therefore only some of them reach maturity [6]. The full body ablation of PPARγ using
epiblast-specific KO mice gives an excellent opportunity to investigate the physiological effects of
global PPARγ deletion in adult mice. The major limitation of the approach is that the pathologies affect
multiple organs and therefore cell autonomous and primary effects are difficult to identify and dissect.
A possible solution could be the development and more systematic usage of total body inducible and
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cell type specific inducible KO models in which the recombination can be induced at will in different
developmental or diseases states.Int. J. Mol. Sci. 2016, 17, 1236 7 of 22 
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Figure 4. Gene editing strategies applied to the mouse PPARγ allele. The different targeting approaches
that have been described i the literature are summarized in this figure.
3.2. eterozygous PPARγ Mice
ice heterozygous for PPARγ showed increased insulin sensitivity instead of the expected insulin
resistance. These mice showed decreased triglyceride content in metabolic relevant organs due to
elevated leptin expression and induction of fatty acid metabolism [72]. Heterozygous PPARγ mice are
resistant to high fat diet (HFD) induced obesity and under these conditions, remained more sensitive
to insulin than their WT counterparts [73]. This effect may be caused by the release of some genes
that are repressed by PPARγ in adipose tissue. Although they use different mechanisms, activation
and partial loss of PPARγ both increase insulin sensitivity [74]. Deletion of one PPARγ allele not only
affected lipid storage, but mainly in fasting conditions, also reduced the expression of genes involved
in glucose uptake and utilization, fatty acid synthesis, lipolysis and glycolysis. These deregulations led
to reduce circulating adiponectin levels in the WAT. Expression of metabolic genes decreased in WAT,
but was not affected in liver and skeletal muscle. In addition, there was a decrease in the metabolic
rate and physical activity of the PPARγ+/´ mice, which was abolished by thiazolidinedione treatment,
thereby linking regulation of the metabolic rate and physical activity to PPARγ [75].
3.3. Hypomorph Mouse Model
Targeting the exon B of adipose tissue specific PPARγ2 isoform generated the PPARγ KO in
WAT (Fi ure 4). These mice lso displayed d reased levels of PPARγ1 [76]. The homozygous
(PP Rγhyp/hyp) mice are born normally, indicating th t the PPARγ2 isoform may not be required for
placental development. However, these animals present growth retardation, severe lipodystrophy
and about a 40%–50% mortality rate before the age of five weeks. Neonatal PPARγhyp/hyp mice have
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insulin resistance, hyperinsulinemia, hyperglycemia and fatty liver, which resembles to human CGL.
In contrast, adult mice overcome the fatty liver and hyperlipidemia. However, the skeletal muscle
and the heart accumulated more lipids and it was associated with glucose intolerance. The PPARγ
agonist, rosiglitazone, reversed glucose intolerance, but not the insulin resistance in homozygote mice.
Adipogenic markers and PPARγ target genes were reduced. The mild insulin resistance was explained
by an up-regulation of β-oxidation in muscle. However, lipid metabolism and β-oxidation genes in the
liver remained unchanged. This model demonstrates the compensatory mechanisms in the absence of
WAT [76].
3.4. Ablation of PPARγ2 Isoform
Two PPARγ2 KO mouse models were generated [77]. PPARγ2 KO mice generated by Zhang et al.
are viable, but have lipodystrophy and reduced leptin and adiponectin plasma levels. The PPARγ2 KO
mice have insulin resistance in male but not in female mice. Surprisingly, the insulin resistance,
hypertriglyceridemia and liver steatosis in these males could be reversed by PPARγ agonist
treatment, demonstrating that PPARγ2 is not essential for TZDs action on insulin sensitivity [78].
Medina-Gomez et al. generated another PPARγ2 KO mouse model [79] that despite normal adipose
tissue development, exhibit insulin resistance under chow diet, suggesting that PPARγ2 could
modulate insulin sensitivity [79]. In both models in vitro adipocyte differentiation from precursors
is impaired. This suggests a compensating mechanism, which protect in vivo adipogenesis. PPARγ2
deletion in the leptin deficient ob/ob background resulted in decreased fat mass, dyslipidemia, β-cell
failure and insulin resistance. PPARγ2 isoform prevents lipotoxicity by promoting adipose tissue
proliferation and decreasing ectopic lipid deposition in peripheral organs [80].
3.5. PPARγ Mutant Mice
Modeling the human PPARγ dominant negative mutations is important due to its impact in
human metabolic diseases. Therefore, researchers generated mouse lines carrying similar dominant
negative mutations in the PPARγ gene. Tsai et al. [81] generated a mouse model containing the
P465L amino acid substitution in PPARγ (Figure 4), which is the equivalent with human (P467L)
mutation [43]. The homozygous P465L PPARγ mutation is lethal, but the heterozygous animals display
hypertension and altered adipose tissue distribution similarly to human phenotypes. In contrast
with the severe insulin resistance in P467L PPARγ patients, the P465L PPARγ mutant mice have
normal insulin sensitivity. However, P465L mutation shows more similarity to humans on obese ob/ob
backgrounds [82]. Another dominant negative PPARγ (L466A) mouse model shows lipodystrophy,
increased FFA levels, liver steatosis, hypertension and develops mild insulin resistance, when fed
with high-fat diet (Figure 4) [83]. Moreover, mice harboring dominant negative mutations of PPARγ
show altered adipose tissue localization and distribution revealing a role for PPARγ controlling the fat
distribution in the body [81]. One of the models was the knockin of alanine at position 112 (S112A),
which blocks the serine phosphorylation results in a constitutively active PPARγ, with elevated serum
adiponectin and reduced FFA levels on high-fat diet. This result suggests that modulation of PPARγ
phosphorylation may serve as pharmacological target for insulin sensitization [84].
Importantly, the well-known PPARγ2 P12A mutation in human populations was also generated
in mice as a P12A knockin model. Homozygous Ala/Ala mice are viable, however they have lean
phenotype, improved insulin sensitivity and plasma lipid profiles on chow diet. Heikkinen et al.
demonstrates that P12A variant of PPARγ2 is an important modulator in metabolic control, but the
effects depend on the metabolic context and gene–environment interactions [85].
Inducible PPARγ knockin mouse model was also developed in which the endogenous PPARγ gene
was substituted with recombinant inducible PPARγldi allele. The PPARγldi/+ mouse show reduced fat
mass and insulin sensitivity giving a unique model of human conditional lipodystrophy [86].
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3.6. Tissue Specific Ablation of PPARγ
3.6.1. Adipose-Specific PPARγ Knockout
Imai et al. selectively deleted PPARγ in adipocytes of adult mice using the tamoxifen-dependent
Cre-ERt2 recombination system (Figure 4). The mature PPARγ-null white and brown adipocytes die
within a few days, demonstrating that PPARγ is essential for the in vivo survival of mature adipocytes.
After some days without tamoxifen fat depots are replaced with newly formed PPARγ-positive
adipocytes [87].
Two similar adipose-specific PPARγ KO mice have been published both KO mice use floxed
PPARγ knock-in mice crossed with transgenic aP2-Cre mice model. He and colleagues report that
WAT and BAT decreased in young mice, has decreased leptin and adiponectin plasma levels, increased
circulating FFAs and triglycerides; therefore, developing liver steatosis. However, adipose-specific
PPARγ KO mice have insulin resistance in adipose tissue and liver, but not in skeletal muscle when
challenged with high-fat diet. Administration of TZDs to these mice improves insulin sensitivity
in skeletal muscle and liver, but not in adipose tissue [88]. Jones et al. have published the other
adipose-specific PPARγ KO mouse line. These animals exhibited impairment in brown and white
adipogenesis and physiology. When fed with high-fat diet, these mice showed decreased weight gain
despite hyperphagia, increased triglyceride levels, liver steatosis, reduced adiponectin and leptin
levels and did not develop glucose intolerance or insulin resistance [89]. Characterization of in vivo
glucose dynamics pointed to improved hepatic glucose metabolism as the basis for preventing high-fat
diet-induced insulin resistance [89]. The differences between these rather similar models might be
caused by the different expression of aP2-Cre. The aP2 promoter is a direct PPARγ target, such that
PPARγ inactivation during differentiation will reduce the levels of Cre resulting different PPARγ
inactivation and potentially distinct phenotypes. PPARγ activation by TZDs increases the uptake of
fatty acids and the containing capacity of adipocytes. Selective activation of PPARγ in adipocytes can
cause whole body insulin sensitization in mice without an increase of body weight [90]. Models of
adipose tissue-specific impairment of PPARγ function demonstrate that PPARγ activity is necessary
for normal adipose tissue development and maintenance.
Recently, Jonker and colleagues identified the fibroblast growth factor 1 (FGF1) as a critical
transducer in the process of adipose tissue sensing nutrients and it stay under the regulation of PPARγ
via the promoter of FGF1 gene. Interestingly, FGF1 KO have no significant phenotype under standard
laboratory care, these mice develop severe diabetic phenotype and impaired adipose tissue expansion
with multiple pathologies when challenged with a HFD. The phenotype of FGF1 KO mouse establishes
the PPARγ–FGF1 axis as critical for maintaining metabolic homeostasis and insulin sensitization [91].
An in vivo conditional PPARγ KO adipocyte specific (Adipotrack marked cells) was described recently,
and this model has been used to elucidate different cell progenitor depots and its importance in
adipocyte differentiation within developmental and adult stages [92,93].
3.6.2. Muscle-Specific Ablation of PPARγ
Skeletal muscle is one of the main insulin responsive tissues in the body. Although PPARγ is
expressed to a much smaller extent in muscle than in adipose tissue (Figure 1), it is able to induce
the expression of genes that regulate glucose uptake. Two independent groups examined mice with
targeted PPARγ deletion in skeletal muscle using the creatinine kinase promoter driven Cre-loxP
recombination system [94,95]. In the first study, Hevener et al. used older mice and showed that lack of
PPARγ in skeletal muscle resulted in adiposity, severe insulin resistance, and being unable to respond
to TZD treatment [94]. In another study, Norris et al. used younger mice with targeted deletion of
PPARγ in muscle resulting in obese mice with no insulin resistance and remained responsive to TZD
treatment [95]. The role of PPARγ in increasing lipid oxidation in muscle has been published [96].
Findings in muscle-specific PPARγ KO mice suggested that PPARγ in muscle can regulate whole-body
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lipid metabolism and insulin sensitivity, however TZDs have indirect and age dependent effects on
skeletal muscle [14,77,95].
3.6.3. Liver-Specific Disruption of PPARγ
PPARγ is expressed most highly in adipose tissue, but is also detectable in many other tissues
such as liver (Figure 1), where PPARγ expression is increased in several mouse models of liver
steatosis [97,98]. Liver PPARγ disruption has been developed using Cre recombination system driven
by liver-specific albumin promoter [98]. Gavrilova et al. deleted PPARγ in the liver of A-ZIP/F-1
lipoatrophic mice. Lack of PPARγ in this lipoatrophic background protected the mice to develop
fatty liver by reducing liver triglyceride and increasing serum FFA levels, but these mice have muscle
insulin resistance. Liver-specific ablation of PPARγ in mice leads to increased adiposity and insulin
resistance, but these mice respond to TZD treatment [98]. However, liver-specific PPARγ disruption
on a lipoatrophic background results mice becoming resistant to TZD treatment, indicating that in
the absence of WAT, the liver takes over the role of regulating lipid and glucose homeostasis [14,98].
Matsusue et al. also showed that disruption of liver PPARγ in leptin deficient ob/ob mice results
decreased hepatic triglyceride accumulation, but elevated serum lipid levels and insulin resistance [99].
These reinforce the pivotal role of PPARγ in the liver regulating lipid homeostasis and protecting other
organs from lipotoxicity and insulin resistance [77].
3.6.4. PPARγ Ablation in Pancreatic Beta Cells
Pancreatic β-cells also express PPARγ (Figure 1) [100,101], where activation of PPARγ regulates
the expression of genes involved in glucose-stimulated insulin secretion and TZDs can enhance
the insulin secretion and insulin sensitivity in mice and human [102]. Surprisingly, deletion of
PPARγ in mouse β-cells caused altered islet mass and morphology, but do not affect the whole body
glucose homoeostasis. These mice showed weakened TZD response [103]. Another study used a
pancreatic-specific PPARγ KO model generated by crossing mice with floxed PPARγ to mice with
pdx-1 promoter driven Cre recombinase and showed that loss of PPARγ in the whole pancreas results
normal size of β-cell islets, but hyperglycemia and impaired insulin secretion [104]. Vivas et al. shown
that ob/ob mice with genetic ablation of PPARγ2, known as POKO mice failed to enlarged its β-cell
mass. They identified genes that regulate β-cells proliferation and survival and identified some
PPARγ dependent pathways (cholesterol biosynthesis, apoptosis through TGF-β signaling), which are
differentially regulated in POKO mice [105]. However, Welters et al. detected minimal changes in gene
expression of important β-cells genes in tamoxifen-inducible β-cell-specific PPARγ KO mice, which
could be modified with HFD or rosiglitazone treatment. There were no significant differences in body
weight, plasma insulin, glucagon and glucose levels when the mice are kept on normal diet. Based on
this study PPARγ seems to be not directly essential for normal β-cell function [106].
3.6.5. Disruption of PPARγ in Macrophages and Dendritic cells
PPARγ has an important role in many immune cell types [107]. Many studies have been focused
on macrophages and dendritic cells. The PPARγ expression level in these cell types is low, but they have
an important role in regulating expression levels of genes involved in lipid homeostasis and immune
function [108,109]. Macrophages accumulated in adipose tissue in obese state are able to induce
inflammation and affect glucose homeostasis [110]. Generation of inducible macrophage-specific
PPARγKO mouse revealed the importance of this receptor in the macrophages regulation of cholesterol
efflux [111]. Macrophage-directed PPARγ KO mice are more predisposed to obesity and insulin
resistance after challenged with HFD, however these mice do not have liver steatosis [112]. Macrophage
PPARγ has been claimed to be required for normal skeletal muscle and liver insulin sensitivity and for
the maturation of anti-inflammatory M2 type macrophages [113]. More recently it has been shown
that STAT6 acts as a facilitating factor for PPARγ by promoting DNA binding and increasing number
of genes connected to lipid metabolism and inflammatory response in macrophages and dendritic
Int. J. Mol. Sci. 2016, 17, 1236 11 of 22
cells [114]. This work also established that M2 activation at the initial transcriptional response could
take place without PPARγ. In addition PPARγ is a potent regulator of various processes in dendritic
cells; however in vivo model system for DC-specific PPARγ ablation was unavailable for a long time.
A recent study has shown that the dendritic cell-specific CD11c-Cre PPARγfl/fl conditional KO mice
have spontaneous lung inflammation and emphysema. Using genome wide microarray analysis, they
identified potential PPARγ regulated genes in emphysema [115]. Schneider and colleagues found that
PPARγ is required for alveolar macrophage differentiation, however absence of PPARγ did not affect
the development and recruitment of macrophages and dendritic cells in other tissues such as liver,
brain, heart, kidneys, lamina propria and WAT. GM-CSF induces PPARγ expression in fetal monocytes
and plays an important role in alveolar macrophage development. Transcriptome analysis of alveolar
macrophage precursors from newborn mice showed that PPAR confers a unique alveolar macrophage
signature and identity [116].
4. Testing of Novel PPARγ Modulators in Mice
Novel compounds have been developed in the last few years, which might be potential modulators
of PPARγ. One of them is Z-551 that has both PPARα agonistic and PPARγ antagonistic activities.
The effects of Z-551 were examined in wild type mice on HFD and it could suppress body weight gain,
ameliorated insulin resistance and abnormal lipid metabolism, significantly reducing the plasma levels
of glucose, FFAs, insulin and leptin [117]. Another potent modulator is a new thiazolidinedione,
GQ-177, which has shown a therapeutic potential on diet-induced obesity and atherosclerosis.
This molecule was identified as a partial and selective PPARγ agonist, which improved insulin
sensitivity and lipid profile without affecting body weight, fat accumulation or bone density in LDLr-/-
mice fed with high-fat diet [118].
5. Comparison of Human and Mouse Findings
Several years ago Heikkinen et al. [19] already summarized the role of PPARγ in human and
mouse physiology listing the different human mutations found and mouse models generated until
2007. They highlighted the complex function of PPARγ in cell differentiation, inflammation, glucose
and lipid homeostasis pointing ahead its role in metabolic diseases.
In this current review, we provide an update and focused on human and mouse experiments
regarding metabolic syndrome, summarizing the earlier findings and more recent studies as well.
As PPARγ effects occur in a tissue specific manner and the different PPARγ full agonists have severe
side effects, also suggested the need of tissue selective PPARγ modulation. PPARγ allelic variants
are the most common cause of metabolic traits related to the PPARγ gene. However, knockin mice
(P465L) carrying a similar human mutation P467L have normal insulin sensitivity in contrast with the
severe insulin resistance in these patients. This clearly indicates a difference in the response of the
genetic variants between human and mouse. The Pro12Ala mutation of PPARγ2 is a risk factor of
weight gains in human obese patients; in contrast, the Ala12 allele improves insulin sensitivity and has
protective effect against obesity and type 2 diabetes mellitus in lean patients [20,119]. The Pro12Ala
knockin mice show similar phenotypes, the Ala/Ala homozygous animals are leaner and more
insulin sensitive than Pro/Pro mice on normal chow, however they put on weight and lost insulin
sensitivity on HFD. It was suggested that the Pro12Ala variant is a diet-dependent metabolic sensor
with the ability to modify the PPARγ2 efficacy [85]. To our current knowledge this polymorphism
in human and in mouse behaves similarly. Although PPARγ binding is conserved in mouse and
human orthologous regions, there is a marked difference in reclusion of this transcription factor
due to the motif turnover in different species [120]. It is also important to point out that the PPARγ
binding retention during mammalian evolution from mouse to human is C/EBPa interdependent [121].
Differences in PPARγ binding due to SNPs in mouse and human adipose tissue have been also
reported [42]. Adding complexity to the system, polymorphisms in PPARγ cofactors can also affect
insulin and glucose metabolism like PPARGC1A cofactor mutation Gly482Ser. These genes also
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should be considered T2D risk factors [122]. Phosphorylation of PPARγ at Ser273 by cyclin-dependent
kinase 5 (Cdk5) can affect the expression of distinct PPARγ target genes increasing insulin resistance
in mouse models. In obesity a variety of cytokines such as TNFα secreted by adipose tissue can
induce the Cdk5 dependent PPARγ phosphorylation. Mutation of Ser273 to alanine and RSG could
effectively block the Cdk5-mediated phosphorylation of PPARγ [123]. Interestingly, adipose tissue
specific Cdk5 KO mice have increased PPARγ phosphorylation and insulin resistance due to ERK
dependent phosphorylation [124]. Again underscoring the complexity and redundancy affecting
PPARγ activation in vivo.
Mouse full body PPARγ KO MORE-PG does not mimic the human lipodystrophy findings
(Table 2). Although, crossing these mice with the obese ob/ob model may provide some insight into the
human lipodystrophy [98].
On the other hand, Gray et al. hypothesize that manipulations of PPARγ gene in mice generates
very similar defects than in humans but these can only be seen when these mice are challenged with a
HFD, exposure to low temperature, during exercise or food deprivation [82,125] arguing that external
conditions are critical in the development of metabolic phenotypes and diseases in the presence of a
particular genetic disposition.
Another important recent development is the discovery of PPARγ biallelic mutations in a human
patient. These mutations are rare; therefore, fibroblasts and/or tissues derived from these patients are
usually limited. Better full body PPARγ KO mice models are needed to elucidate PPARγ related CGL
(Tables 1 and 3).
In summary it is likely that a better and more strategic integration of mouse and human
phenotypes and data will be possible by direct comparison of disease-in-a-dish type experiments on
human derived iPS cell lines and mouse cellular models. As far as animal models are concerned more
“dynamic” models allowing recombination of PPARγ in a temporal and tissue specific manner can
accelerate the rate of discovery. CRISPR/Cas9 technology can be used to knock out or knock in genes in
whole body animal models and in human cell lines; allowing researchers to study at molecular and
physiological level the effect of this gene disruption. This can also lead to identification of the tissue
and cell type specific roles including tissue-specific gene expression. The extensive usage of genomic
and epigenomic approaches are also going to help dissect the gene expression networks coordinated
by the receptors. The ultimate goal of therapy should be to develop tissue selective PPARγ modulators
to avoid side effects. For this to happen, mouse and human need to go forward hand in hand in an
even more intertwined manner.
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Table 2. Comparison of the metabolic features of PPARγ whole body and tissue-specific KO mice.
Features
Mouse Models
MORE- PG
KO [69]
HET-PPARγ
[72,75]
HYPO- PPARγ
[76]
PPARγ2
KO [78]
Adipo PPARγ
KO [88,89]
Sc.M. PPARγ
KO [94,95]
Liver PPARγ
KO [98]
β-cell PPARγ
KO [103]
MΦ PPARγ
KO [112]
Obesity No Ó Ó No Ó (HFD) Ò (HFD) No No Ò (HFD)
Insuline resistance Yes IS Yes Yes (male) unclear Yes Yes No Yes
Glucose tolerance Ó (male) ND Ó Ó ND Ó ND NC Ó (HFD)
Type 2 diabetes Yes (male) No ND ND Yes Yes ND No ND
Lipodystrophy Yes No Yes Yes Yes No No ND ND
Liver steatosis No No No No Yes ND No ND No
Hypertension hypoten. ND ND ND ND ND ND ND ND
Organomegaly Yes No No No ND Yes No ND No
Food intake NC Ó NC NC Ò (HFD) Ó NC ND ND
Triglicerides Ò Ó Ó NC Ò Ò Ò * ND NC
Free fatty acids Ò Ó Ò (fed) ND Ò Ò NC ND ND
Cholesterol ND ND ND ND ND ND NC ND LDL Ó
Glucose Ò ND Ò (fed) NC NC Ò Ò * NC Ò (HFD)
Insulin Ò Ó Ò ND Ò Ò Ò * NC Ò (HFD)
Leptin Ó Ò Ó Ó Ó Ò Ò * ND Ò
Adiponectin Ó Ò Ó Ó Ó ND Ó * ND Ó
TZD effectiveness ND Yes ND Yes partial partial Yes Yes Yes
HET = heterozygous; HYPO = hypomorph; Adipo = adipocyte; Sc. M. = skeletal muscle; MΦ = macrophage; HFD = on high fat diet; IS = insulin sensitivity; hypoten = hypotension;
male = just in male mice; fed = in fed state; * = only in 40 weeks old mice; NC = not changed; ND = not determined.
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Table 3. Comparison of the metabolic features between human and mouse PPARγ mutants.
Features
Human Mutants Mouse Mutants
P12A Mutant [20] P467L Mutant [43,65] F388L Mutant [64] Biallelic E138V R164W [52] P12A Mutant [85] P465L Mutant [81]
Obesity Yes No No No No No
Insuline resistance Yes Yes Yes Yes IS No
Glucose tolerance ND Ó ND ND Ò Ò
Type 2 diabetes Yes Yes Yes Yes No No
Lipodystrophy No No FPLD3 CGL No redistr.
Liver steatosis ND ND No ND ND ND
Hypertension ND Yes Yes No ND Yes
Organomegaly No ND No Yes No ND
Food intake ND ND ND ND NC NC
Triglicerides Ò Ò Ò Ò Ó NC
Free fatty acids ND ND ND ND NC NC
Cholesterol Ò HDL Ó HDL Ó NC Ó NC
Glucose Ò ND Ò Ò NC NC
Insulin ND Ò Ò Ò NC Ò (HFD)
Leptin ND ND ND Ó NC ND
Adiponectin ND ND ND Ó NC ND
TZD effectiveness ND ND partial ND partial ND
FPLD3 = familiar partial lipodystrophy 3; CGL = congenital generalized lipodystrophy; HFD = on high fat diet; HDL = high-density lipoprotein; IS = insulin sensitivity;
NC = not changed; redistr. = redistribution of adipose tissue; ND = not determined.
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6. Conclusions
Mice have many genes in common with humans (99% of human genes are conserved in mouse
genome) and show many similarities in organ physiology, metabolic processes and pathogenesis of
different diseases. Mice are excellent model organisms for other reasons as well. First of all, they
are small in size and have a short generation time, which makes breeding and housing relatively
simple and cost-effective. Second, since the mouse genome is known, the use of genetically modified
mouse models in research and preclinical studies has increased. Furthermore, the mouse is the only
mammalian model in which it is technically possible to replace a particular mouse gene with its human
counterpart. These so-called “humanized” mouse models are able to produce the human version of
the protein of interest, or it can be created to carry a mutated version of the human gene, which is
known to be associated with a human disease.
Comparing the findings from human and mouse PPARγ related metabolic diseases, we can
conclude that mice models can generally be used to investigate and more deeply understand the
processes of human diseases. However, it is important to know that despite genetic and physiological
similarities, mice have a lot of specific features, which make it difficult to extrapolate mouse results
to human. Moreover, there are different conditions in mice, such as genetic background, gender,
age, diet and environmental conditions, which could further modify the results. In the last decade,
genome-wide studies have changed the epidemiological and functional research of PPAR variants in
both human and mouse. However, more systemically used epigenetic and transcriptomic analyses
are necessary in the different PPARγ mouse mutants for elucidating PPARγ and its cistrome’s role in
metabolic syndrome. The future of PPARγ research relies on using humanized mouse models coupled
with human iPS cells derived tissues and genome-wide studies for not only clarify the molecular
mechanism of PPARγ in its target genes that have an impact on metabolic syndrome conditions,
but also to find suitable PPARγ modulators for human insulin resistance and diabetes treatment.
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